# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Post-transplant lymphoproliferative disease

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 17 results.
Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy
Status: Recruiting
Last Changed: Jul 24, 2018
First Received: Jan 22, 2014
Disease(s): Posttransplant Lymphoproliferative Disorder
Intervention(s): Rituximab sc, Rituximab sc consolidation, Rituximab sc combined with CHOP chemotherapy, Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx
Locations: Uniklinik RWTH Aaachen Klinik für Onkologie, Hämatologie und Stammzell-transplantation Med. Klinik IV, Aachen, Germany
Charite Universitätsmedizin Berlin Campus Mitte, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Berlin, Germany
Charité - Universitätsmedizin Berlin CCM Medizinische Klinik m. S. Nephrologie, Berlin, Germany
Universitätsklinikum Bonn Med. Klinik III/ZIM Hämatologie/Onkologie, Bonn, Germany
DIAKO Bremen gGmbH, Klinik für Hämatologie und Onkologie, Bremen, Germany
... and 17 other locations.
Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab
Status: Recruiting
Last Changed: Dec 23, 2019
First Received: Jan 05, 2018
Disease(s): Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD), Stem Cell Transplant Complications, Lymphoproliferative Disorders
Intervention(s): tabelecleucel
Locations: University of California San Diego Moores Cancer Center (Adults Only), La Jolla, California, United States
Children's Hospital of Colorado (Pediatrics Only), Aurora, Colorado, United States
Lombardi Comprehansive Cancer Center (Adults and Pediatrics), Washington, District of Columbia, United States
University of Miami Leonard M. Miller School of Medicine - Miami Transplant Institute (Adults only), Miami, Florida, United States
Winship Cancer Institute of Emory University (Adults only), Atlanta, Georgia, United States
... and 23 other locations.
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
Status: Recruiting
Last Changed: Dec 23, 2019
First Received: Jan 09, 2018
Disease(s): Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Intervention(s): tabelecleucel
Locations: University of California San Diego Moores Cancer Center (Adults only), La Jolla, California, United States
University of California Davis Comprehensive Cancer Center (Adults only), Sacramento, California, United States
Yale University (Adults and Pediatrics), New Haven, Connecticut, United States
Lombardi Comprehansive Cancer Center (Adults and Pediatrics), Washington, District of Columbia, United States
University of Florida (Adults and Pediatrics), Gainesville, Florida, United States
... and 28 other locations.
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
Status: Recruiting
Last Changed: Jun 13, 2019
First Received: Apr 27, 2017
Disease(s): Post-transplant Lymphoproliferative Disease, Transplant-Related Hematologic Malignancy
Intervention(s): Autologous EBV-CTL transduced with vector SFG-CNA12, Autologous EBV-CTL transduced with control vector SFG-CNA8, Leucapheresis
Locations: Great Ormond Street Hospital, London, United Kingdom
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
Status: Recruiting
Last Changed: Aug 15, 2019
First Received: Oct 20, 2015
Disease(s): Epstein-Barr Virus Infections, Post-Transplant Lymphoproliferative Disorder, Lymphoma
Intervention(s): Group A, Group B
Locations: Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada
Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Apr 27, 2016
First Received: Apr 27, 2016
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): bendamustine, rituximab
Locations: Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of
EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients
Status: Recruiting
Last Changed: Dec 10, 2019
First Received: Dec 06, 2019
Disease(s): EBV Infection, EBV Viremia, Epstein-Barr Virus Associated Lymphoproliferative Disorder, Post-transplant Lymphoproliferative Disorder
Intervention(s): EBV DNA in whole blood and plasma
Locations: Aarhus University Hospital, Aarhus, Central Region Of Denmark, Denmark
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Status: Available
Last Changed: Apr 05, 2019
First Received: Jul 04, 2016
Disease(s): Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Epstein-Barr Viremia, Lymphoma, AIDS-related, Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Primary Immunodeficiency (PID), Leiomyosarcoma (LMS), Nasopharyngeal Carcinoma (NPC), Epstein-Barr Virus-associated Lymphoproliferative Disease (EBV+ LPD) With Acquired Immunodeficiency (AID), Solid Organ Transplant Complications, Stem Cell Transplant Complications
Intervention(s): tabelecleucel
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Status: Recruiting
Last Changed: Jun 06, 2019
First Received: Dec 29, 2017
Disease(s): Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
Intervention(s): Everolimus, Tacrolimus, Mycophenolate Mofetil
Locations: Children's of Alabama, Birmingham, Alabama, United States
Phoenix Children's Hospital, Phoenix, Arizona, United States
Loma Linda University, Loma Linda, California, United States
Children's Hospital Los Angeles, Los Angeles, California, United States
UCLA Mattel Children's Hospital, Los Angeles, California, United States
... and 21 other locations.
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia
Status: Recruiting
Last Changed: Mar 13, 2019
First Received: Jun 03, 2014
Disease(s): Post-transplant Lymphoproliferative Disorder, B-Cell Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Recurrent Lymphoplasmacytic Lymphoma
Intervention(s): cyclophosphamide, laboratory biomarker analysis, Bendamustine Hydrochloride, Etoposide, Fludarabine Phosphate, Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Locations: City of Hope Medical Center, Duarte, California, United States